Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
NCT02030860Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paricalcitol in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Started Jan 2014; status: completed.
02
Drugs
paricalcitol
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02030860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030860.